The misuse of injectable diabetes medications over the past two years has led pharmaceutical companies to develop alternative treatments for weight loss, addressing shortages that affected diabetic patients worldwide, including in Cyprus. Drugs containing semaglutide and tirzepatide, marketed as Ozempic, Wegovy and Mounjaro, have been at the centre of this trend. Ozempic has long been … Continue reading Diabetes, weight-loss injections see increased use and new options in Cyprus